Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Accessibility StatementSkip Navigation HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of l ...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update Accessibility StatementSkip NavigationConference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provid ...

Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent US12,564 ...

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Accessibility StatementSkip Navigation HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfD ...

Core Viewpoint - Resverlogix Corp. is experiencing delays in completing its year-end audit, which will prevent the company from meeting the March 31, 2026 deadline for filing its Annual Filings [1] Group 1: Audit and Filing Delays - The company anticipates it will not meet the March 31, 2026 deadline for filing Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025 [1] - The auditor has indicated that the audit of the annual financial statements is unlikely to be completed by the deadline, with an expected completion date of April 10, 2026 [1] Group 2: Management Cease Trade Order - Resverlogix has applied to the Alberta Securities Commission for a management cease trade order (MCTO) that would restrict the trading of the company's securities by its CEO and CFO until the Annual Filings are submitted [2] - The ASC has not yet made a decision on the MCTO application, which could either be granted or result in an issuer cease trade order if delays continue [2] Group 3: Compliance and Reporting - The company is committed to completing the Annual Filings as soon as possible and will issue a news release once they are filed [3] - Until the Annual Filings are submitted, the company will adhere to guidelines set out in NP 12-203, including bi-weekly default status reports [3] Group 4: Insider Trading Blackout - Members of the company's management and other insiders are subject to an insider trading blackout until the Annual Filings are completed [4] - There have been no material business developments since the interim financial reports were filed on November 13, 2025 [4] Group 5: Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases [5] - The company is a leader in epigenetics and is developing a new class of therapies aimed at regulating disease-causing gene expression, particularly focusing on cardiovascular disease and post COVID-19 conditions [6]

Core Insights - Oryzon Genomics has received patent protection for its cancer therapy involving iadademstat in combination with PD-1 or PD-L1 inhibitors, specifically targeting small cell lung cancer (SCLC) [1][2] - The patent is expected to provide protection until at least 2040, enhancing Oryzon's intellectual property portfolio globally [2][3] - Iadademstat is currently undergoing clinical trials in combination with immune checkpoint inhibitors for extensive-stage SCLC, with promising preliminary results [3][5] Company Overview - Oryzon Genomics, founded in 2000 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine for oncology and CNS disorders [4] - The company has a robust clinical portfolio, including two LSD1 inhibitors: iadademstat for oncology and vafidemstat for CNS disorders, with ongoing Phase I and II studies [4][5] - Iadademstat has shown a 100% overall response rate in acute myeloid leukemia (AML) and is being evaluated in various hematological and solid tumors, including SCLC [5][6] Clinical Development - Iadademstat is being tested in two ongoing clinical trials for extensive-stage SCLC, one sponsored by the U.S. National Cancer Institute and the other by Yale University [3][6] - The drug has demonstrated safety and efficacy in combination with other therapies, including azacitidine and venetoclax for AML, and is also being explored for non-oncological indications [5][6] - Oryzon has received orphan drug designation for SCLC and AML in both the US and EU, indicating its potential significance in treating these conditions [6]

Core Insights - VolitionRx Limited has announced the completion of validation for its automated Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems, marking a significant advancement in veterinary diagnostics [1] - The automated test is expected to enhance efficiency in veterinary hospitals, with over 1,700 facilities in Japan already registered to use the test since its launch in July 2024 [1] - The partnership with Fujifilm Vet Systems presents a substantial revenue opportunity for Volition, given the large market of approximately seven million pet dogs in Japan [1] Company Overview - Volition is a multinational epigenetics company focused on developing blood tests for early disease detection, including cancer, with a commitment to improving outcomes for both humans and animals [1] - The company operates research and development activities primarily in Belgium, with additional offices in the U.S. and London [1] - Volition's technology platform demonstrates synergy between human and veterinary diagnostics, utilizing the same automated analyzer platform for both [1] Market Context - Cancer is identified as the leading cause of adult canine deaths, and early detection through the Nu.Q® Vet Cancer Test can significantly improve treatment outcomes [1] - Fujifilm Vet Systems, a subsidiary of Fujifilm Holdings Corporation, is a key player in the Japanese veterinary diagnostics market, providing services to approximately 11,000 veterinary medical facilities [1] - The automated testing capability is expected to meet the increasing demand for rapid and high-throughput diagnostic solutions in veterinary medicine [1]

Financial Overview - Oryzon Genomics reported a strong cash position of $33.3 million (€28.4 million) at the end of 2025, following a financial turnaround with over $60 million secured in the first half of 2025 [4][14]. - Research and development (R&D) expenses for Q4 2025 were $5.2 million, totaling $14.8 million for the year, compared to $2.1 million and $8.7 million in the same periods of 2024 [12]. - General and administrative expenses were $1.7 million for Q4 2025 and $5.6 million for the full year, up from $0.9 million and $3.7 million in 2024 [12]. - The net loss for Q4 2025 was $2.1 million, with a total net loss of $6.7 million for the year, compared to losses of $1.1 million and $4.6 million in 2024 [13][14]. Oncology Developments - Iadademstat, Oryzon's lead oncology program, is currently involved in seven ongoing trials, with six sponsored by the National Cancer Institute (NCI) or leading U.S. institutions [4][6]. - The drug has shown a 100% overall response rate (ORR) in first-line acute myeloid leukemia (AML) trials, with no dose-limiting toxicities reported [4][8]. - Preliminary data from the ALICE-2 Phase Ib trial indicated a 100% ORR and 90% strict complete remission (CR) in newly diagnosed AML patients [8]. - A new Phase Ib trial of iadademstat in combination with immune checkpoint inhibitors and radiotherapy for extensive-stage small cell lung cancer (ES-SCLC) has commenced [8]. CNS Program Updates - Oryzon has appointed Dr. Rolando Gutierrez as Chief Medical Officer for CNS programs, enhancing its medical and regulatory capabilities [4][7]. - The company is preparing for a protocol resubmission to the FDA for the Phase III PORTICO-2 trial in aggression in Borderline Personality Disorder (BPD) [13]. - Oryzon is expanding its Phase IIb schizophrenia trial into additional EU countries and finalizing preparations for a new Phase II trial in aggression in autism spectrum disorder (ASD) [7][13]. Intellectual Property and Future Trials - Oryzon has strengthened its intellectual property protection for iadademstat, with a patent application granted in Japan, expected to remain in force until at least 2040 [9]. - The company plans to initiate a clinical trial for iadademstat in essential thrombocythemia (ET) following EMA approval [8]. - Oryzon's earlier stage program, ORY-4001, a selective HDAC6 inhibitor, is progressing through IND enabling studies for neurological diseases [11].

With your diet during pregnancy, you're programming your baby's DNA. And this is going to have an impact on your baby's development and on their future risk of disease. And there's a lot of pregnant moms who are eating a diet that's not giving them the nutrients their baby needs. This is not the mom's fault. This is the fault of our food system. This is the fault of society. And nobody's telling moms about this. And I wanted to create this guide to help parents navigate that food system and see easy things ...

Core Insights - VolitionRx Limited has made significant clinical and commercial progress, highlighting licensing momentum and advancements in various diagnostic technologies [1][2] Group 1: Licensing and Commercialization - The company is in active discussions with approximately 10 global diagnostic leaders for licensing agreements [1][2] - Anticipated announcements of additional agreements during 2026 as negotiations progress [2] Group 2: Clinical Developments - The Nu.Q® NETs assay is included in a $7.3 million government-backed DETECSEPS program in France for early sepsis detection [1] - A reimbursement submission for lung cancer testing in France is underway, with routine clinical use expected by Q4 2026 [1] - New clinical utility of the Nu.Q® NETs assay has been demonstrated for managing Hidradenitis Suppurativa, a disease affecting about 1% of the global population [1] Group 3: Market Opportunities - The Capture-Seq™ platform presents a $23 billion annualized opportunity in cancer detection [1][2] - The total addressable market for Nu.Q® NETs in sepsis and chronic conditions is estimated at $3.8 billion [2] - The Nu.Q® Vet (Canine/Feline) market is projected to exceed $1 billion, with the canine test already commercially available [2] Group 4: Veterinary Breakthroughs - The Nu.Q® Vet Feline assay achieved 100% specificity in detecting feline lymphoma, marking a significant advancement in veterinary diagnostics [1] - This breakthrough is expected to unlock a $5 million milestone payment upon publication in a peer-reviewed journal [1]